Welcome to Digital Health Summit

3. Digital Health Summit

 22th November 2022, Budapest, Corinthia Hotel

Hungary’s first Digital Health conference. Digital health conference for public and private health care, digital pharma, and manufacturers of digital medical products.


Digital Health Business Market + AI Roche Personalized Healthcare +
Data and Cyber Security + Health Gadgets +
Digital Health Venture + Pharma Digital +
Telemedicine +
Digital Health Sciences + Innovative Healthcare

Keynote speakers

Bernd Grabner

Bernd Grabner was born in 1975 and started his studies of law and business economics in Linz in 1993. Already during his studies he started working in the family owned wholesaling company in 1999, being in charge for an alternating range of operational tasks. Bernd Grabner became member of the board of GM Pharma in 2003. After the merger with Jacoby Pharmazeutika in July 2013, he now is member of the board of Jacoby GM Pharma and therein responsible for the divisions supplier relations, key account management for dispensing doctors and new business activities.

Takács Péter
State Secretary for Health
Ministry of Interior

He graduated from the Faculty of Medicine of Semmelweis University in 2005. He worked as
a resident physician at Semmelweis University in the field of forensic medicine from 2005 to
2009, and between 2010 and 2012 he was engaged in the planning and organization of drug
safety studies. Between 2012 and 2015 he worked as a health specialist at the Institute of
Pharmaceutical and Health Quality and Organizational Development, later he became a
medical consultant and acting regional director of the State Health Care Center. From 2015 to
2017 he was head of the Department of Finance and director of Outpatient Care of North-
Central Buda Centre, St. John Central Hospital Budapest. From 2017 to 2019 he headed the
Health Policy Department of the Ministry of Human Capacities. Between 2019 and 2020 he
became acting director-general of the North-Central Buda Centre, St. John Central Hospital
Budapest. Lately he was deputy director-general for Primary and Specialist Care at the
National Healthcare Service Center.

Public duties:
He was president of the Hungarian Resident Association from 2005 to 2008, and between
2005 and 2009 he was a member of the Board of Governors of Semmelweis University, and
between 2007 and 2015 he was a member of the National Board of the Hungarian Medical


The 2nd Digital Health Summit was September 30th, 2021. We had 421 guests and 21 journalists attended. The 1st Digital Health Summit was in February, 2020 with 397 attendees. And our DHS's little sister conference: Digital Health Essential was in 30th May, 2022 with 265 guests. 

The Digital Health Summit brings together public and private health care, digital pharma, and manufacturers of digital medical products, venture capitalists ynd startups from around Hungary, to network, exchange ideas and to become more familiar with opportunities in Hungary. Our independent conference will become a significant event for many companies in the DH industry and is particularly important in Hungary given the explosion of business and entrepreneurship in the region.

Digital health is the convergence of digital technologies with health, healthcare, living, and society to enhance the efficiency of healthcare delivery and make medicines more personalized and precise. The discipline involves the use of information and communication technologies to help address the health problems and challenges faced by people under treatment. These technologies include both hardware and software solutions and services, including telemedicine, web-based analysis, email, mobile phones and applications, text messages, wearable devices, and clinic or remote monitoring sensors. Generally, digital health is concerned about the development of interconnected health systems to improve the use of computational technologies, smart devices, computational analysis techniques, and communication media to aid healthcare professionals and their clients manage illnesses and health risks, as well as promote health and wellbeing.

Digital health is a multi-disciplinary domain involving many stakeholders, including clinicians, researchers and scientists with a wide range of expertise in healthcare, engineering, social sciences, public health, health economics and data management.

Who attends
  • + Providers / Health Systems
  • + Payers
  • + Pharma
  • + Health Tech
  • + Platform Technology Pioneers
  • + Big Tech
  • + Investors
Why attend?
  • + INSPIRED. Our speakers are leading real business transformation, driving change across the enterprise and actioning measurable digital innovation for their businesses. Get motivated from leaders and walk away with new ideas you can implement.
  • + CHALLENGED. Rethink your current processes and business blueprints, the event speakers will challenge your way of thinking and allow you to realise that new methods may be your best way of moving forward sitting alongside your current beliefs.
  • + TRANSFORMED. The conference agenda and speakers are put together as such to reveal insights into how some of the biggest organisations are going about digital, from real business use cases to success stories and where the challenges may lie.
  • + NETWORKING. It's an invaluable part of events and where real value often presents itself, meeting those who are facing the same challenges and coming together to solve similar issues. Our agendas feature numerous opportunities throughout the day to meet like minded folk from various industries and backgrounds. We have previously had extremely positive feedback from delegates who have found long lasted business relationships with those who they wouldn't normally meet from opposite industries and largely seeking out the same solutions to industry wide transformation sticking points.


Dress code

business formal


AP Summit Now Kft. és Molnár Rita Judit egyéni vállalkozó

Social media

join us

Companies registered for the 2022 conference

AbbVie, Astrazeneca, Atlas Pharma, Bay Zoltán Alkalmazott Kutatási Közhasznú Nonprofit, Belügyminisztérium, Berlin Chemie, Biogen, Bismogel, BENU, Boehringer Ingelheim RCV Magyarországi Fióktelepe, Carbyne Consulting, Dermus, DP Innovations, Édes Gyermekünk Alapítvány, Egis Gyógyszergyár, Egészségkalauz, EitHealth InnoStars e V, Eötvös Loránd Tudományegyetem Természettudományi Kar Fizikai Intézet, ESZFK, Egészségügyi Technológia és Orvostechnikai Szállítók Egyesülete, E-Med4All Europe, Euromedic International Hungária, Euromedic- Pharma, EVisit, Fitt Praxis, Foglaljorvost.hu, HARTMANN-RICO HUNGÁRIA, Házipatika, Hungaropharma, Hunt&r, Inspira Research, Jacsomedia, Mathias Corvinus Collegium Alapítvány, Medistance, MediAd, Medipredict, MSD Pharma Hungary, Népszava, Novartis Hungaria, Novodata, Oracle Hungary, OTP Egészségpénztár, Oncompass, OnForge, Phoenix Pharma, Richter Gedeon, Roche, Swedish Orphan Biovitrum s.r.o Magyarországi Fióktelepe, Telex, Tritonlife, Pearl Hungary, Semmelweis Egyetem, Synlab, Szintézis-NET, Szinapszis, QCG Consulting, QTICS Group, Valor Capital, Webbeteg, Wolf Theiss Faludi Ügyvédi Iroda (Attorneys-At-Law)


The pandemic accelerated the adoption of digital health tools, with the sector expected to exceed $400 billion by 2027. What mechanisms can be put in place to continue leveraging new digital health technologies for an efficient healthcare sector and a healthier population? - panel discusson - pending



general manager
Roche Hungary

Raffaella Claudia Bondi is an experienced pharmaceutical executive, with 20+ years in marketing and commercial roles, across several health-related businesses. She has been working at Roche for nearly 20 years. From diagnostics via the pharmaceutical industry to diabetes care, she gained experiences in many areas. She began her career in Italy, her home country, then held various positions at the affiliate in Denmark. In Switzerland, she became responsible for the entire European region, since November 2021 she is the General Manager of Roche Hungary. Passionate about partnering for better patient outcomes. She’s committed to co-creating with different stakeholders across the Hungarian healthcare ecosystem to ensure sustainability, access as well as boost innovation.

Hungarian physicist, university professor
ELTE University

A Magyar Tudományos Akadémia levelező tagja. 
1989-ben szerzett biofizikus diplomát az Eötvös Loránd
Tudományegyetemen. 1992-ben szerzett doktori fokozatot. A doktori
értekezésének a címe: Neuronhálózat modellek vizsgálata és
alkalmazása. 2003-ban habilitált az ELTE-n. 2008-ban lett a Magyar
Tudományos Akadémia doktora. 2019-ben lett a Magyar Tudományos
Akadémia levelező tagja. 1992 és 2006 között több részletben
vendégkutató a Johns Hopkins Egyetemen, Baltimore-ban. 1993 és 2001
között a ELTE Bolyai Kollégium vezető tanára. 1992-ben egyetemi
tanársegéd kinevezést kapott az ELTE Atomfizikai Tanszékém. 1998-ban
egyetemi adjunktus lesz az ELTE Komplex Rendszerek Fizikája Tanszékén,
majd 2002-ben docensi kinevezést kap. 2009-től egyetemi tanár szintén
az ELTE Komplex Rendszerek Fizikája Tanszékén. 2010 és 2011 között
látogató professzor a The John Hopkins Egyetemen. 2015-ben az ELTE
Fizikai Intézet professzor tanács elnökévé választották. Csabai István
kutatásai a fotometrikus vöröseltolódások meghatározása, az univerzum
nagyskálás szerkezetére fókuszálnak. Ezenfelül éredklődik a nagy,
komplex tudományos adatbázisok fejlesztése a modern számítástudomány
eszközeivel, virtuális obszervatóriumok iránt is. Mindemellett
kutatási területei közé tartozik a nagy mennyiségű tudományos adat
statisztikai elemzése, adatbányászat, mesterséges intelligencia, a
komplex rendszerek és komplex hálózatok vizsgálata, számítógépes-,
szociális- és pénzügyi hálózatok elemzése, a bioinformatika, új
generációs génszekvenálási adatok elemzése, és a rák-genomika.

Solvo Biotechnology

He is a serial entrepreneur and investor, he has founded or co-founded over two dozen companies. He’s the founder and CEO of Solvo Biotechnology, the largest biotech company in Hungary. He is the founder and president of the Hungarian Biotech Association and of Medipredict, a company in the personalized health prevention and prediction field. He is an investor in 20+ startups and focuses on early stage companies in the areas of life sciences/medtech/AI/blockchain. He is an associate professor at the University of Szeged since 2003, where he teaches Biotechnology and Entrepreneurship and he also gives lectures at the Aquincum Institute of Technology. He is the founder of a school in Szeged, called Szikra. Szikra is a practical and experience-centered nonprofit institution, its goal is to become a world class primary and secondary school.


Dr. Feller Antal 1986-ban szerezte doktorátusát a Budapesti Műszaki Egyetem Vegyészmérnöki Karán. Az Egis Gyógyszergyárnál folytatott kutatói munkáját követően piaci elemzőként dolgozott. 1999-ben szerződött a Hungaropharma Gyógyszerkereskedelmi Zrt.-hez, melyet 2010 óta vezérigazgatóként irányít. Dr. Feller Antal a Gyógyszer-nagykereskedők Szövetségének elnöke, 2021-ben pedig az Európai Gyógyszer-nagykereskedők Szövetségének (GIRP) igazgatósági tagjává választották, ahol a kis és közepes országok szövetségeit tömörítő szekciót képviseli, ezen felül tagja a GIRP gazdasági és szociális ügyekkel foglalkozó bizottságának, valamint a szállítási lánc megoldásokkal foglalkozó tanácsadó testületnek.

Oppenheim Law Firm

Graduated from the Janus Pannonius University of Pécs in 1998 and pursued postgraduate studies in EU law at the University of Pécs. Obtained an LLM in International Economic Law at the University of Warwick in 2004. Attended the University of Oxford as a Chevening scholar and received a Magister Juris degree in 2006. Joined the Budapest office of Freshfields Bruckhaus Deringer in 2005. Associate of Oppenheim since 2007, partner at the firm since 2010. Head of the Corporate practice of Oppenheim since 2014.
Areas of specialization: Company Law, M&A, Capital MarketTransactions.
Sector experience: Capital markets, Chemicals & Pharma
Languages: Hungarian and English

Hungarian Chamber of Pharmacists

1977-79 között közforgalmú gyógyszertárban (Salgótarján), 1982-ig kórházi gyógyszertárban (Kerepestarcsa), 1990-ig galenusi laborban (Pest megyei Gyógyszertári Központ) beosztott, illetve részlegvezető gyógyszerész. 1997-ig a Pharmafontana kiadói tevékenységért felelős főmunkatársa, osztályvezetője, majd patikaprivatizációért felelős privatizációs igazgatója. Ezt követően az MGYT kiadói tevékenységének vezetője. 1991-től a Gyógyszerészet felelős szerkesztője. Első felelős szerkesztője a Gyógyszerészi Hírlapnak (1989-1991) és a Gyógyszertárnak (2001-2007). 1995-től alelnöke, majd 1998-tól 2007-ig elnökségi tagja a MOSZ-nak.

Az MGYK elnökségi tagja 1998-2000 között, Pest megyei Szervezetének elnökségi tagja 2002-2006 között, az MGYK alelnöke 2007-től, elnöke 2011-től. 2015-ben elnöki pozíciójában újraválasztották.

Feleségével 1992-ben jogelőd nélküli magángyógyszertárat létesít. Két felnőtt gyermeke és öt unokája van. Felesége, gyermekei és gyermekeinek házastársai valamennyien gyógyszerészek.

Chief Operating Officer, Sales Director
PHOENIX Pharma Zrt.

Tamás Kaló is the COO and Sales Director of PHOENIX Pharma Zrt, and  Vice President of the Hungarian Association of Pharmaceutical Wholesalers.

Tamás graduated in 1995 in economics and has been working for PHOENIX since 1996.   He supported the activities of PHOENIX Hungary as Financial Director between 2002-2020, during the time the Company became the market leader wholesaler partner of the Hungarian pharmacies. He took over the duties of Chief Operating Officer and Sales Director in 2020, focusing on innovative services for customers in the pharmaceutical supply chain. He considers an important task to support the digital development of the sector, in which the wholesale industry – directly linked with the pharmaceutical industry, pharmacies and hospitals – plays a key role. By the digital improvement of logistics, sales and administrative processes of the pharmaceutical supply chain, patients can have faster, safer and more efficient access to the medicines they need, and to important healthcare products, that prevent diseases.

Innovation and Managing Director, Consultant, Owner

Balázs has an MA in Economics and works for Szinapszis from the beginning as the professional leader of researches, also responsible for internal innovation and international relationships.  Balázs is a developer Szinapszis’ branded pharmaceutical solutions and research models. Main research areas: sales force effectiveness, pharmaceutical targeting, segmentation, KOL mapping, price sensitivity tests, MCM and digital transition in the pharma industry. Presenter on various Hungarian and International conferences, member end representative of Szinapszis in the European market research associations (ESOMAR, EphMRA).

Country Director
Biogen Hungary

Dr. Ákos Kókai-Nagy is currently the Country Director of the Hungarian Affiliate of Biogen

pharmaceutical company since 2017. Also, he is a Board member of the Association of Innovative Pharmaceutical Manufacturers (AIPM) since 2017, and the elected President of the organization since

2020. Dr. Ákos Kókai-Nagy graduated from Semmelweis University and, after several further courses, he graduated in 2012 with an EMBA qualification from Purdue University International Master of Management. During his career, he has held management positions at several pharmaceutical companies both in Hungary and abroad, including since 2012 he has been the Managing Director of Astellas Pharma in Denmark.

general manager
OTP Egészségpénztár

A Pécsi Egyetemen 2003-ban szerzett közgazdasági diplomát pénzügyi eszközök és intézmények szakon, melyet követően másfél évet dolgozott pénzügyi területen, majd átkerült az Országos Egészségbiztosítási Pénztárhoz, ahol kezdetben osztályvezetői minőségben a kiemelten nagy értékű gyógyszerekért volt felelős. Néhány év elteltével a Gyógyszerügyi Főosztály Finanszírozási és Statisztikai főosztályvezető-helyettesévé nevezték ki, ahol az Országos Egészségbiztosítási Pénztárnál végzett munkája elismeréseként 2008-ban „Szent Kristóf“ díjban részesült. Az OEP-nél töltött évek alatt az Európai Bizottság munkájába bekapcsolódva Magyarország szakmai érdekképviseletében is részt vett és a nevéhez fűződik az első országtanulmány készítése is, mely Magyarország gyógyszer finanszírozásáról szól. 2010 óta az OTP Egészségpénztár értékesítési és marketing-kommunikációs igazgatója, és 2020 decembere óta pedig ügyvezető igazgató a Pénztárnál. Számos olyan fejlesztés és eredmény köthető tevékenységéhez, mint például az online feltöltés/befizetés bevezetése, vagy a Big Data elemzésen alapuló automatikus kommunikáció kialakítása. Az elmúlt időszakban pedig a Pénztár digitalizációs valamint szervezeti és személyzeti hatékonyságra vonatkozó stratégiáját dolgozta ki. 2006 óta regisztrált mérlegképes könyvelő, sőt ezen túlmenően 2012 és 2014 között megszerezte második diplomáját is Szent István Egyetem Gazdaság- és Társadalomtudományi Karán, Egészségügyi gazdálkodási és stratégiai specialista szakon. Jelenleg a Magyar Egészségkommunikációs Egyesület és a Magyar Egészség-gazdaságtani Társaság tagja.

Business Development Director
Egis Pharmaceuticals PLC

Klára Marton, MD is the Business Development Director of Egis Pharmaceuticals PLC /owned by Servier/, one of the leading generic pharmaceutical companies in the CEE and CIS regions with activities extending from research and development, active ingredient and finished product pharmaceutical production to sales and marketing. Her priorities at Egis is leading international strategic business development, defining mid- and long-term pipeline consists of value-added products, commodity generics, biosimilar products, hard-to-make generics, products with intellectual property advantage, medical devices and digital patient solutions. She is also responsible for licensing-in and strategic partnerships. Under her leadership the early involvement of customer insight in business development, especially patient insight has been established. She is the Vice Chair of the Value Added Sector Group of Medicines for Europe, which represents pharmaceutical companies in Europe and is the voice of the generic, biosimilar and value added industries. Before Egis she worked as a Business Unit Director with responsibilities ranging from marketing, sales to market access covering several therapeutic fields (prescription products and media driven portfolio as well) at GSK, Sanofi-Aventis in Budapest. Earlier she held commercial positions at multinational innovative companies in Hungary and consulting company in the US. She is a Medical Doctor and holds a Master of Business Administration degree.

Health Policy Expert & Health Economist

As a Health Policy Expert of the Hungarian National Public Health Centre since 2017, Fruzsi is strategically planning and implementing evidence-based developments in the field of primary care. She is currently working on improving care of six chronic disease groups that are leading causes of death in Hungary (e.g. hypertension, diabetes, oncological diseases etc.). She graduated as a Medical Anthropologist from Durham University in 2017 and received her MSc in Health Policy, Planning and Financing from ELTE in 2019. Stemming from her research background, she is an advocate of evidence-based policy making and aims to disseminate the idea of data collection and analytics to systematically address leading health issues. Working on national and international health care projects, primarily in the field of chronic care, she has first-hand experience in the barriers of implementing innovative digital solutions in the public health sphere. She works to overcome these barriers.

founder, Digital Health Summit

Rita Molnar earned her BA business communication degree in the Budapest College of Communication and Business in 2008. She completed her MBA master program at Budapest Metropolitan University in 2020 and she is now pursuing a Health Policy, Planning and Financing Master’s program at Budapest Corvinus University. The program is designed to provide you with a comprehensive understanding of the complexities of health care systems both at macro- and micro-levels within the context of technological development, an ageing population and patient expectations. She is well-prepared to work in health administration, government departments, research and consultancy agencies, universities, national health services, health care organizations and pharmaceutical and medical device industry. 

She started her career as a professional photojournalist from 1997 to 2002. Rita was just 21 when she started organizing events, and she founded her own company. Her first event was an amateur film festival in Eger in 1998. Ever since, she has been organizing 2 conferences per year, mainly in the medical, VC investing and banking fields. Between 2001-2005 Rita also worked as a movie producer. She was involved in co-producing a movie directed by the iconic Magyar movie-maker Miklós Jancsó. From 2006 to late 2007 Rita managed the event marketing team at Ringier Publishing, a Hungarian subsidiary of a Swiss-based leading publishing firm. In the summer of 2010 Rita founded Slimexpo with a venture capital involvement, and she organized with her own team a Slimexpo Festival with a diet, health and beauty theme at a premium event venue in Budapest Aréna in the spring of 2011. 

CEO, Oncompass Medicine

Istvan Petak, MD, Ph.D., is a physician and researcher. He has been developing technologies together with his team to find the best personalized, targeted therapy for cancer patients for over 20 years. His group was one of the pioneers of predictive molecular diagnostics. Their current development is a method to match the best, targeted therapy to each genetic alterations or combination of genetic changes in every cancer patient. This technique is being implemented into an artificial intelligence-based medical software system. This system and method received the award of the American  Society Clinical Oncology at their Breakthrough Oncology conference in Bangkok, and it also won the innovation prize of the GET IN THE RING V4, in 2019. Dr. Petak is the founder and CEO of Oncompass Medicine and regular lecturer of the Semmelweis University, Budapest, and the University of Illinois at Chicago.

Digital Lead
Novartis Hungaria

Tamás graduated as an economist and began his pharmaceutical career at Pfizer in 2009. During his more than 10 years there, he gained extensive experience in various departments (Finance, Business operation, Global Commercial operation), which was later utilized in the field of sales force excellence and he also played a decisive role in the company's digital development and implementation of new systems. After nearly 10 years on the support side, he had the opportunity to prove his abilities on the business side, for a year and a half in the Internal Medicine business unit he was responsible for promoting selected products through digital channels. He joined Novartis’s cardiovascular business unit as a product manager in 2020 and will continue his career in the Digital Lead position from 2021, where his main responsibilities will be the company’s digital development, mapping and implementing new, innovative opportunities and transforming the Omnichannel approach theory into practice.

medical doctor, health care manager

Balazs has been graduated at the Semmelweis Medical School in 1992, then he got a further MSc degree at the London School of Hygiene and Tropical Medicine & London School of Economics and Political Science,  Public Health and Policy Health Care Management,  where he has continued his further studies at the Health Services Research Unit. Furthermore he has also graduated at the Eötvös Lóránd Science University Faculty of Social Sciences Health Economics Task Force on Drug Policy and Pharmaceutical Economics. His work experience encompasses wide range of health care sector: He has served as a General Practitioner, managing a public health institution, worked at the Ministry of Health, World Bank Public health programs, and also used to be director at the Pharmaceutical sector, as well as Private Health Insurance, Health Fund. He is proud to be the founder of the first Hungarian private health insurance providing in-kind care, or establishing health fund, and also he has participated in the foundation of the first Hungarian Fund Holding primary care model. With his 12 colleagues he is managing a medical devices distributor firm, besides he is providing health economics, health care management, health policy advices to several health insurance companies, health care providers. He is also the health policy advisor of the Major of Budapest. 

deputy director of the Development Department, 77 Elektronika Kft

Barnabás is an engineer-economist with extensive experience in the medical device and diagnostics field.
He graduated from the Budapest University of Technology as a mechanical engineer in 2003 and did his postgraduate studies at the Budapest Corvinus University.
He started his career at the Budapest University of Technology, where he was involved in an international cardiovascular stent research and development project.
In 2007 he began to work at MED-EL GmbH. in Austria as a development project lead in the implantable neurostimulation field.
In 2011 he joined the Hungarian In Vitro Diagnostic company 77 Elektronika Kft. as diabetes topic manager and became soon deputy director of the Development Department. His responsibility is cross-functional device development of multiple product lines from idea to market release in international environment, including quality and regulatory aspects. His main area is Point of Care Testing and related digital health technologies.
Barnabás is a strategic planner with a high focus on medical product related innovation.
He is married and father of 3 children.

Member of the Board
Cashline Investments, Valor Capital

He graduated at the Budapest University of Economic Sciences and Public Administration as a financial investment analyst and risk manager in 2003. He has more than 12-years experience in venture capital and private equity investments, as well as, strategic and financial management of companies. Between 2003 and 2007 he worked for the Hungarian Development Bank (MFB) and MFB Invest Zrt. His position was investment analyst, he was responsible for the analysis of development plans, company valuation, the support of the operation of the portfolio companies, and the exit from the investments. He is working for Cashline Group since 2007 as a portfolio-manager, active in the deal flow generation, project analysis, valuation, management of the entire investment and exit process, as well as, strategic management of the portfolio companies. Since 2012 he is responsible for the venture capital activity of Cashline Group, and is the CEO of Valor Capital. He completed a Ph.D. Program at Corvinus University of Budapest, on the Department of Environmental Sciences and Technology in 2015. His research topics are environmental innovations and patents. He is managing director and board member of numerous Hungarian small and medium-sized enterprises.

Cluster Country Director
AstraZeneca, Czech Republic, Slovakia and Hungary

Kuuno’s main mission is to secure all healthcare (HC) experts (patient organization groups, doctor associations, political decision makers, health insurance, hospital leaders, universities, medicines developers and other parties) are working in close collaboration securing continuously improved outcomes for patients.

He is especially focused on how we can be faster implementing new medical guidelines in real clinical practice and how we can improve and optimize patient pathways in HC using HC digitalization and data.

As an experienced leader of medicine developer Kuuno is doing all possible to build up x-functional teams to lead and drive innovation in all countries together with all HC partners.

Kuuno joined AstraZeneca in 2007 and has 20 years of experience in the industry with proven results in leading market access and business units in various therapeutic areas in Estonia, Baltics, Czech Republic, Slovakia and Hungary, and also as a member of the leadership teams in Nordics and CEE region. Kuuno holds a Pharmacy Degree from Tartu University in Estonia. Kuuno is based in Prague.

His mission outside of work is to keep family, friends and colleagues in a good spirit and fit enjoying together numerous outdoor sports activities.

Country President
Novartis Magyarország

Matt Zeller is currently leading the Hungarian organization as Country President. Previous Novartis roles include executive director of U.S. cardiovascular national hospital accounts, vice president and head of U.S. patient and specialty services, U.S. sales and marketing head of the COPD franchise, and director of global pharma strategy in Switzerland. Before joining Novartis, Matt was a principal in BCG’s New Jersey and Shanghai offices in the commercial pharma space. Prior to BCG, he worked in hospital marketing and pharma sales for Lilly. Matt holds a Bachelor of Science from Vanderbilt University and an MBA from Duke University.